KRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessment.

KRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessment.

<h4>Background</h4>Monoclonal antibodies directed against the epidermal growth factor receptor (EGFR) have been approved for the treatment of patients with metastatic colorectal carcinoma (mCRC) that do not carry KRAS mutations. Therefore, KRAS testing has become mandatory to chose the m...

Full description

Bibliographic Details
Main Authors: Nicola Normanno, Carmine Pinto, Francesca Castiglione, Alberto Bardelli, Marcello Gambacorta, Gerardo Botti, Oscar Nappi, Salvatore Siena, Fortunato Ciardiello, Gianluigi Taddei, Antonio Marchetti
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2011-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22216189/?tool=EBI

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22216189/?tool=EBI

Similar Items